Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-04-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021年度募集资金存放与实际使用情况的专项报告" which translates to "2021 Annual Report on the Storage and Actual Use of Raised Funds." It details the amount of funds raised through convertible bonds, the timing of fund receipt, the specific projects funded, the usage and balance of the raised funds, and compliance with regulatory guidelines. It also includes detailed tables showing the use of funds, investment progress, and approvals from board meetings and shareholders. The document is focused on the management and use of capital raised by the company, specifically related to fundraising activities and the deployment of those funds. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive (8438 characters) and contains detailed financial and project usage data, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2022-04-11 Chinese
2021年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度监事会工作报告" which translates to "2021 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of financial reports, internal controls, compliance with laws and regulations, and plans for 2022. It includes references to the audit report and financial statements but does not itself contain full financial statements or detailed financial data. The document is a report from the supervisory board summarizing their oversight work rather than a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on supervisory activities. This fits best under the category of Audit Report / Information (AR), which includes reports on audit results and supervisory board work related to financial and compliance oversight, excluding full annual reports. The document length is 4224 characters, which is substantive but not extremely long, consistent with a supervisory board report. Therefore, the classification is AR with high confidence. FY 2021
2022-04-11 Chinese
中航证券有限公司关于公司2021年度持续督导培训情况的报告
Regulatory Filings Classification · 95% confidence The document is a report from Zhonghang Securities Co., Ltd. regarding the 2021 continuous supervision training for Jianfan Biotechnology Group Co., Ltd. It references regulatory guidelines from the Shenzhen Stock Exchange and details the training content, participants, and conclusions. The document is relatively short (1157 characters) and focuses on a specific supervisory training event rather than financial results, management changes, or shareholder votes. It does not contain financial statements or earnings data, nor is it an announcement of a report publication. The content aligns with regulatory compliance and supervisory activities related to the company's governance and regulatory adherence. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance reports that do not fit other specific categories.
2022-04-11 Chinese
2021年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2021年度董事会工作报告" which translates to "2021 Annual Board of Directors Work Report." It contains detailed information about the company's business performance, operational review, R&D, production, marketing, human resources, and risk factors for the year 2021. It also includes detailed descriptions of board meetings, committee activities, and plans for 2022. The content is comprehensive and covers management's discussion and analysis of the company's performance and outlook. This aligns with the characteristics of a Management Reports (MDA) filing, which provides detailed explanations of financial results, business trends, and outlook. It is not a full Annual Report (10-K) as it lacks full financial statements and audit opinions, nor is it a simple announcement or presentation. Therefore, the document is best classified as a Management Reports (MDA).
2022-04-11 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of various reports and proposals related to the 2021 fiscal year, including the 2021 Annual Report, Supervisory Board Work Report, Financial Statements, Audit Report, Internal Control Report, Profit Distribution Plan, and other governance matters. The document states that the full reports are published separately on the official disclosure website (cninfo.com.cn) and that these resolutions will be submitted to the 2021 Annual General Meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's meeting decisions and approvals. The length is 3514 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or Audit Report (AR).
2022-04-11 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 33rd meeting of the 4th Board of Directors of the company, including approval of the 2021 Annual Report, financial statements, audit report, internal control report, profit distribution plan, remuneration plans, and other governance matters. It references the 2021 fiscal year and mentions that these reports and documents are published on the official disclosure website. The document is not the annual report itself but a board meeting resolution announcement that approves and submits these reports to the shareholders' meeting. The length is 4142 characters, which is relatively short and mainly contains meeting resolutions rather than full financial data or reports. Therefore, it is best classified as Board/Management Information (MANG) because it announces board meeting decisions and management reports approval, not the full annual report or audit report itself.
2022-04-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.